Atea’s AT-527, an oral antiviral drug candidate reduces viral replication in hospitalized patients with COVID-19 in phase 2 interim analysis

Dear Investor,

Please find attached a press release from our partner Atea Pharmaceuticals:
https://ir.ateapharma.com/news-releases/news-release-details/ateas-527-oral-antiviral-drug-candidate-reduces-viral

Do not hesitate to contact us for any further questions.

With best regards,